AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19001248 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 300 mg/d
Number of subjects: 537
Study 19001248 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 800 mg/d
Number of subjects: 537
Study 19001248 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 1,600 mg/d
Number of subjects: 537
Study 19001248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 15746990 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss with normal calcium intake (1 g/day)
Number of subjects: 66
Study 15746990 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss with high calcium intake (1.7 g/day)
Number of subjects: 66
Study 15746990 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance with normal calcium intake (1 g/day)
Number of subjects: 66
Study 11931600 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance enhancement intervention using a problem-solving format
Number of subjects: 63
Study 11931600 — intervention group
Group type: COMPARATOR
Intervention: Standard disposition planning
Number of subjects: 63
Study 11931600 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance enhancement intervention using a problem-solving format (after covarying barriers)
Number of subjects: 63
Study 11931600 — intervention group
Group type: COMPARATOR
Intervention: Standard disposition planning (after covarying barriers)
Number of subjects: 63
Study 10467203 — intervention group
Group type: EXPERIMENTAL
Intervention: saruplase
Number of subjects: 255
Study 10467203 — intervention group
Group type: COMPARATOR
Intervention: streptokinase
Number of subjects: 255
Study 8750419 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter insertion task
Number of subjects: 0
Study 8750419 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter deletion task
Number of subjects: 0
Study 8750419 — intervention group
Group type: EXPERIMENTAL
Intervention: Process dissociation paradigm applied to letter insertion task
Number of subjects: 0
Study 8750419 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion condition in letter insertion task
Number of subjects: 0
Study 2141110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ultrafiltration (UF; 1 litre/h)
Number of subjects: 8
Study 2141110 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical correction (BC; 3 h)
Number of subjects: 8
Study 2141110 — intervention group
Group type: COMPARATOR
Intervention: Biochemical correction (BC) during BC-UF
Number of subjects: 8
Study 2141110 — intervention group
Group type: COMPARATOR
Intervention: Sequential ultrafiltration (UF) during BC-UF
Number of subjects: 8
Study 2141110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ultrafiltration (UF)
Number of subjects: 8
Study 2141110 — intervention group
Group type: COMPARATOR
Intervention: Biochemical correction (BC) in UF-BC sequence
Number of subjects: 8
Study 2141110 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical correction (BC)
Number of subjects: 8
Study 6109648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg every eight hours for a maximum of three days during menstruation for three consecutive cycles)
Number of subjects: 35
Study 6109648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 35
Study 6109648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 30073784 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Diabetes Training Program (WB-DTP)
Number of subjects: 50
Study 30073784 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 30442174 — intervention group
Group type: COMPARATOR
Intervention: Standard dissemination
Number of subjects: 2313
Study 30442174 — intervention group
Group type: COMPARATOR
Intervention: Type 1 facilitation
Number of subjects: 2313
Study 30442174 — intervention group
Group type: COMPARATOR
Intervention: Type 2 facilitation
Number of subjects: 2313
Study 28024268 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressor group
Number of subjects: 0
Study 28024268 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25294277 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1049
Study 25294277 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1049
Study 25294277 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1049
Study 25294277 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 1049
Study 24534317 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanyl and propofol injection (Group A)
Number of subjects: 60
Study 24534317 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone hydrochloride (Group B)
Number of subjects: 60
Study 20376076 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol (5-10 mg/day) for 8 weeks
Number of subjects: 43
Study 18362593 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA CTrach
Number of subjects: 271
Study 18362593 — intervention group
Group type: COMPARATOR
Intervention: LMA Fastrach
Number of subjects: 271
Study 17395027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 17395027 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 0
Study 12699210 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glucocorticoid and beta‐agonist (n = 52)
Number of subjects: 129
Study 12699210 — intervention group
Group type: COMPARATOR
Intervention: Control children of the same age (n = 20)
Number of subjects: 129
Study 12699210 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid alone (n = 23)
Number of subjects: 129
Study 12699210 — intervention group
Group type: COMPARATOR
Intervention: Beta‐agonist alone (n = 11)
Number of subjects: 129
Study 12699210 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in group 1 with C/U ratio above 6 (n = 24)
Number of subjects: 129
Study 11084569 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap repair
Number of subjects: 112
Study 11084569 — intervention group
Group type: COMPARATOR
Intervention: Approximation repair
Number of subjects: 112
Study 9378464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy (CT) for ALL
Number of subjects: 31
Study 7901258 — intervention group
Group type: COMPARATOR
Intervention: Dapiprazole administered as directed by its manufacturer after pupil dilation with proparacaine 0.5%, hydroxyamphetamine 1.0%, and tropicamide 0.25%.
Number of subjects: 26
Study 3961029 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-methionine (SAMe) 400 mg single dose and seven daily administrations
Number of subjects: 0
Study 3961029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3961029 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with monoamine oxidase inhibitors (MAOIs)
Number of subjects: 0
Study 31112543 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based adherence clubs
Number of subjects: 775
Study 31112543 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based adherence clubs
Number of subjects: 775
Study 31112543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (lost from club-based care)
Number of subjects: 775
Study 31112543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (referred to standard care)
Number of subjects: 775
Study 30290675 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA pivotal trials
Number of subjects: 12
Study 30290675 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS original trials
Number of subjects: 12
Study 30290675 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA approvals
Number of subjects: 12
Study 30290675 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS NCDs
Number of subjects: 12
Study 26014154 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 336
Study 26014154 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 336
Study 26014154 — intervention group
Group type: COMPARATOR
Intervention: Negative group
Number of subjects: 336
Study 27709234 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit nutritional counselling
Number of subjects: 208
Study 27709234 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultation nutritional counselling
Number of subjects: 208
Study 27709234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no follow-up)
Number of subjects: 208
Study 23689544 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 36
Study 23689544 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS)
Number of subjects: 36
Study 23689544 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS and DXA combined
Number of subjects: 36
Study 23689544 — intervention group
Group type: COMPARATOR
Intervention: ECW/ICW measurement
Number of subjects: 36
Study 20705561 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (H0648g)
Number of subjects: 628
Study 20705561 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Control in H0648g)
Number of subjects: 628
Study 20705561 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy (H0649g)
Number of subjects: 628
Study 20705561 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy (H0650g)
Number of subjects: 628
Study 18192851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 6625
Study 18192851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6625
Study 15928305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment (8-10 mg/kg of body weight; 661 participants)
Number of subjects: 1285
Study 15928305 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (624 participants)
Number of subjects: 1285
Study 12595838 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg per day, increased to 150 mg per day after 411 patients enrolled)
Number of subjects: 1000
Study 12595838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 12595838 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1000
Study 12595838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Metoprolol and Placebo)
Number of subjects: 1000
Study 10482216 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat Well and Keep Moving Program
Number of subjects: 479
Study 10482216 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 479
Study 8599788 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with sodium bicarbonate (NaHCO3)
Number of subjects: 42
Study 8599788 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 42
Study 8599788 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 42
Study 3048075 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose and 40 g fat
Number of subjects: 21
Study 3048075 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g fructose and 40 g fat
Number of subjects: 21
Study 3048075 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g sucrose and 40 g fat
Number of subjects: 21
Study 3048075 — intervention group
Group type: COMPARATOR
Intervention: 40 g fat alone
Number of subjects: 21
Study 1098687 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol applied to the normal skin surrounding psoriatic lesions
Number of subjects: 36
Study 1098687 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated lesions)
Number of subjects: 36
Study 31900187 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + palliative care (UC + PC)
Number of subjects: 22
Study 31900187 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 22
Study 31609930 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) 50/200/25 mg
Number of subjects: 472
Study 31609930 — intervention group
Group type: COMPARATOR
Intervention: Stay on baseline regimen (SBR)
Number of subjects: 472
Study 27000071 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS therapy for 10 weeks
Number of subjects: 49
Study 27000071 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TENS therapy)
Number of subjects: 49
Study 25529995 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message with a stranger
Number of subjects: 98
Study 25529995 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message with a companion
Number of subjects: 98
Study 25529995 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction condition (mobile phone game)
Number of subjects: 98
Study 25529995 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative management
Number of subjects: 98
Study 23826304 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 77036
Study 23826304 — intervention group
Group type: COMPARATOR
Intervention: Comparison subjects
Number of subjects: 77036
Study 23826304 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (for >30 days)
Number of subjects: 77036
Study 22027687 — intervention group
Group type: EXPERIMENTAL
Intervention: BES
Number of subjects: 1707
Study 18672115 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-abortal insertion and staff training (Period 2)
Number of subjects: 2172
Study 18672115 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-abortal insertion, staff training, and simplified screening (Period 3)
Number of subjects: 2172
Study 18672115 — intervention group
Group type: COMPARATOR
Intervention: Control period (Period 1)
Number of subjects: 2172
Study 18672115 — intervention group
Group type: COMPARATOR
Intervention: Nearby agency (no interventions implemented)
Number of subjects: 2172
Study 21315635 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 346
Study 21315635 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 346
Study 21315635 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D and SF-6D
Number of subjects: 346
Study 16028147 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine-artesunate (MAS3)
Number of subjects: 499
Study 16028147 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 4-dose course of dihydroartemisinin-piperaquine (DP4)
Number of subjects: 499
Study 16028147 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily regimen of dihydroartemisinin-piperaquine (DP3)
Number of subjects: 499
Study 16028147 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 499
Study 16028147 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP4)
Number of subjects: 499
Study 11824390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy with cisplatin based chemotherapy
Number of subjects: 0
Study 11824390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy with hyperthermia
Number of subjects: 0
Study 11824390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy, cisplatin, and hyperthermia
Number of subjects: 0
Study 9533120 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic assisted venous drainage (KAVD)
Number of subjects: 50
Study 8308183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cat immunotherapy (2.5 x 10(6) allergy units or 436 U Fel d I administered over 3 months)
Number of subjects: 53
Study 8308183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8308183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cat immunotherapy
Number of subjects: 53
Study 2740549 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's advice to quit smoking
Number of subjects: 424
Study 2740549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physician's advice)
Number of subjects: 424
Study 1092131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous iron 2000 mg after each blood donation
Number of subjects: 58
Study 1092131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous iron 1000 mg after each blood donation
Number of subjects: 58
Study 1092131 — intervention group
Group type: COMPARATOR
Intervention: Placebo after each blood donation
Number of subjects: 58
Study 1092131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous iron 2000 mg after four months between donations
Number of subjects: 58
Study 31612475 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 23
Study 31612475 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 23
Study 31612475 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal oral intake during nutrition support
Number of subjects: 23
Study 31612475 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional beta lactam antibiotics
Number of subjects: 23
Study 31612475 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer length of hospital stay
Number of subjects: 23
Study 29763572 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 4287
Study 26690313 — intervention group
Group type: EXPERIMENTAL
Intervention: BND 600 mg
Number of subjects: 148
Study 26690313 — intervention group
Group type: EXPERIMENTAL
Intervention: BND 1,200 mg
Number of subjects: 148
Study 26690313 — intervention group
Group type: COMPARATOR
Intervention: PLB
Number of subjects: 148
Study 25155931 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined OPRM1 118A>G and COMT 472G>A genotype
Number of subjects: 64
Study 25155931 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 64
Study 23121377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1445
Study 23121377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1445
Study 20460233 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (2 g/d)
Number of subjects: 79
Study 20460233 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study 25159904 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (ProActive)
Number of subjects: 365
Study 16103586 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 42
Study 16103586 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil-artesunate
Number of subjects: 42
Study 12441210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine-CR
Number of subjects: 19
Study 12441210 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 19
Study 10065061 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day training course in building and maintaining patients' trust (intervention group)
Number of subjects: 412
Study 10065061 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians not receiving the training)
Number of subjects: 412
Study 7486087 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 5 micrograms/mL
Number of subjects: 66
Study 7486087 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl 10 micrograms/mL
Number of subjects: 66
Study 2178382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program (training session)
Number of subjects: 40
Study 2178382 — intervention group
Group type: COMPARATOR
Intervention: Normal daily activity
Number of subjects: 40
Study 2178382 — intervention group
Group type: COMPARATOR
Intervention: Control period (24 hours without exercise training)
Number of subjects: 40
Study 2178382 — intervention group
Group type: EXPERIMENTAL
Intervention: Training session
Number of subjects: 40
Study 519838 — intervention group
Group type: EXPERIMENTAL
Intervention: Wright nebulizer
Number of subjects: 20
Study 519838 — intervention group
Group type: COMPARATOR
Intervention: Dosimeter-DeVilbiss apparatus
Number of subjects: 20
Study 31655508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg tablet given the night before and 1 hour before the operation)
Number of subjects: 54
Study 31655508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg tablet)
Number of subjects: 54
Study 31655508 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given at the same times as pregabalin)
Number of subjects: 54
Study 26124455 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedural anticoagulation (AC) for routine prophylaxis (n=869, median duration 4 days)
Number of subjects: 2932
Study 26124455 — intervention group
Group type: COMPARATOR
Intervention: No post-procedural anticoagulation (AC) (n=2063)
Number of subjects: 2932
Study 26124455 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedural anticoagulation (AC) for routine prophylaxis
Number of subjects: 2932
Study 24121184 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:40:10 mixture of MCT, soybean oil, and fish oil (treatment)
Number of subjects: 32
Study 24121184 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (control)
Number of subjects: 32
Study 23352857 — intervention group
Group type: EXPERIMENTAL
Intervention: LipoCol Forte capsules or powder
Number of subjects: 0
Study 23352857 — intervention group
Group type: EXPERIMENTAL
Intervention: LipoCol Forte
Number of subjects: 0
Study 23352857 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin tablets
Number of subjects: 0
Study 21347767 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased water consumption through lessons on water and provision of water fountains and water bottles (behavioral and environmental intervention)
Number of subjects: 0
Study 21347767 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0
Study 19876673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 198
Study 19876673 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Remediation (CR)
Number of subjects: 198
Study 17298423 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus add-on omalizumab
Number of subjects: 0
Study 17298423 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 14517707 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 50 mg
Number of subjects: 18